INJE PharmacoGenomics Research Center

· Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL, Kim EY, Cho YS, Babaoglu MO, Shin JG

Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research (cPMTb)

Br J Clin Pharmacol. 88(3):1159-1169 / 2022.03 [LINK]

· Abed AF, Jarrar YB, Al-Ameer HJ, Al-Awaida W, Lee SJ

The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats (cPMTb)

Curr Pharm Des. 28(4):324-330 / 2022.02 [LINK]

· Jarrar YB, Jarrar O, Abaalkhail SJ, Kalloush HM, Naser W, Zihlif M, Shhab MA, Madani AE, Jamous Y, Lee SJ

Molecular toxicological alterations in the mouse hearts induced by sub-chronic thiazolidinedione drugs administration (cPMTb)

Fundam Clin Pharmacol. 36(1):143-149 / 2022.02 [LINK]

· Jarrar Y, Lee SJ

Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates (cPMTb)

J Pers Med. 12(1):104 / 2022.01 [LINK]

· Cho YS, Bae KS, Choi SC, Cho JM, Lim HS

Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis (cPMTb)

Clin Ther. 44(1):67-80.e1 / 2022.01 [LINK]

· Pham VH, Nguyen VL, Jung HE, Cho YS, Shin JG

The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population (cPMTb)

BMC Med Genomics 3;15(1):3 / 2022.01 [LINK]

· Long NP, Heo DY, Park SO, Yen NTH, Cho YS, Shin JG, Oh JY, Kim DH

Molecular perturbations in pulmonary tuberculosis patients identified by pathway-level analysis of plasma metabolic features (cPMTb)

PLoS One.24;17(1):e0262545 / 2022.01 [LINK]

· Cho YS, Bae KS, Choi SC, Cho JM, Lim HS

Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis (cPMTb)

Clin Ther. 44(1):67-80.e1 / 2022.01 [LINK]

· Long NP, Phat NK, Yen NTH, Park SO, Park YM, Cho YS, Shin JG

A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction (cPMTb)

Tuberculosis (Edinb). 131:102138 / 2021.12 [LINK]

· Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park YM, Choi YK, Phuong NTT, Shin JG

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis (cPMTb)

J Clin Pharmacol. 61(12):1567-1578 / 2021.12 [LINK]

Publications

Product